{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:47:04Z","timestamp":1787028424218,"version":"build-2736575974"},"reference-count":56,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Novel biomarkers are desired to improve risk management for patients with atrial fibrillation (AF). We measured 179 plasma miRNAs in 83 AF patients using multiplex qRT-PCR. Plasma levels of eight (i.e., hsa-miR-22-3p, hsa-miR-128-3p, hsa-miR-130a-3p, hsa-miR-140-5p, hsa-miR-143-3p, hsa-miR-148b-3p, hsa-miR-497-5p, hsa-miR-652-3p) and three (i.e., hsa-miR-144-5p, hsa-miR-192-5p, hsa-miR-194-5p) miRNAs showed positive and negative correlations with CHA2DS2-VASc scores, respectively, which also showed negative and positive correlations with catheter ablation (CA) procedure, respectively, within the follow-up observation period up to 6-month after enrollment. These 11 miRNAs were functionally associated with TGF-\u03b2 signaling and androgen signaling based on pathway enrichment analysis. Seven of possible target genes of these miRNAs, namely TGFBR1, PDGFRA, ZEB1, IGFR1, BCL2, MAPK1 and DICER1 were found to be modulated by more than four miRNAs of the eleven. Of them, TGFBR1, PDGFRA, ZEB1 and BCL2 are reported to exert pro-fibrotic functions, suggesting that dysregulations of these eleven miRNAs may reflect pro-fibrotic condition in the high-risk patients. Although highly speculative, these miRNAs may potentially serve as potential biomarkers, providing mechanistic and quantitative information for pathophysiology in daily clinical practice with AF such as possible pro-fibrotic state in left atrium, which would enhance the risk of stroke and reduce the preference for performing CA.<\/jats:p>","DOI":"10.3390\/ijms21072444","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T11:57:14Z","timestamp":1585828634000},"page":"2444","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Exploratory Analysis of Circulating miRNA Signatures in Atrial Fibrillation Patients Determining Potential Biomarkers to Support Decision-Making in Anticoagulation and Catheter Ablation"],"prefix":"10.3390","volume":"21","author":[{"given":"Naoki","family":"Kiyosawa","sequence":"first","affiliation":[{"name":"Specialty Medicine Research Laboratories I, Daiichi Sankyo Co., Ltd., Tokyo 140-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0301-8906","authenticated-orcid":false,"given":"Kenji","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Biomarker &amp; Translational Research Department, Daiichi Sankyo Co., Ltd., Tokyo 140-0005, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Morishima","sequence":"additional","affiliation":[{"name":"Medical Science Department, Daiichi Sankyo Co., Ltd., Tokyo 103-8426, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-8464","authenticated-orcid":false,"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo 106-0031, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoharu","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo 106-0031, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Arita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo 106-0031, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo 106-0031, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4769-5925","authenticated-orcid":false,"given":"Shinya","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo 106-0031, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2009","article-title":"Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal","volume":"91","author":"Schotten","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_2","first-page":"754","article-title":"Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation","volume":"89","author":"Maass","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"De Jong, A.M., Van Gelder, I.C., Vreeswijk-Baudoin, I., Cannon, M.V., Van Gilst, W.H., and Maass, A.H. (2013). Atrial Remodeling Is Directly Related to End-Diastolic Left Ventricular Pressure in a Mouse Model of Ventricular Pressure Overload. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072651"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.21037\/atm.2019.07.101","article-title":"Current status of oral anticoagulant reversal strategies: A review","volume":"7","author":"Rawal","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/CRD.0000000000000246","article-title":"Should Every Patient with Atrial Fibrillation and a CHA2DS2-VASc Score of 1 Be Anticoagulated? A Systematic Review of 37,030 Patients","volume":"27","author":"Neefs","year":"2019","journal-title":"Cardiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1093\/eurheartj\/eht328","article-title":"Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: The AMADEUS trial","volume":"34","author":"Apostolakis","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e007414","DOI":"10.1161\/CIRCEP.119.007414","article-title":"Catheter Ablation Versus Medical Therapy for Atrial Fibrillation","volume":"12","author":"Asad","year":"2019","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14779072.2018.1510317","article-title":"Catheter ablation for atrial fibrillation: Current patient selection and outcomes","volume":"16","author":"Walsh","year":"2018","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8302326","DOI":"10.1155\/2019\/8302326","article-title":"Biomarkers of atrial fibrillation: Which one is a true marker?","volume":"2019","author":"Ardhianto","year":"2019","journal-title":"Cardiol. Res. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1126\/science.1149460","article-title":"Switching from repression to activation: MicroRNAs can up-regulate translation","volume":"318","author":"Vasudevan","year":"2007","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fphys.2014.00015","article-title":"Atrial fibrillation and microRNAs","volume":"5","author":"Santulli","year":"2014","journal-title":"Front. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/cvr\/cvq350","article-title":"MicroRNAs and atrial fibrillation: New fundamentals","volume":"89","author":"Wang","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fmed.2017.00074","article-title":"microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases","volume":"4","author":"Komici","year":"2017","journal-title":"Front. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lopez, J.P., Diallo, A., Cruceanu, C., Fiori, L.M., LaBoissi\u00e8re, S., Guillet, I., Fontaine, J., Ragoussis, J., Benes, V., and Turecki, G. (2015). Biomarker discovery: Quantification of microRNAs and other small non-coding RNAs using next generation sequencing. BMC Med. Genom., 8.","DOI":"10.1186\/s12920-015-0109-x"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/1476-4598-9-306","article-title":"Serum microRNAs as non-invasive biomarkers for cancer","volume":"9","author":"Brase","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jjcc.2019.05.018","article-title":"MicroRNAs: Emerging biomarkers for atrial fibrillation","volume":"74","author":"Komal","year":"2019","journal-title":"J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10557-017-6736-z","article-title":"MicroRNAs in Atrial Fibrillation: From Expression Signatures to Functional Implications","volume":"31","author":"Kawasaki","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Liang, Y., Ridzon, D., Wong, L., and Chen, C. (2007). Characterization of microRNA expression profiles in normal human tissues. BMC Genom., 8.","DOI":"10.1186\/1471-2164-8-166"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.111.060061","article-title":"Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation","volume":"126","author":"Lane","year":"2012","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jacc.2007.09.064","article-title":"Atrial Fibrosis: Mechanisms and Clinical Relevance in Atrial Fibrillation","volume":"51","author":"Burstein","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00395-017-0647-9","article-title":"Transforming growth factor-beta-mediated CD44\/STAT3 signaling contributes to the development of atrial fibrosis and fibrillation","volume":"112","author":"Chang","year":"2017","journal-title":"Basic Res. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jacc.2010.09.049","article-title":"Association of Left Atrial Fibrosis Detected by Delayed-Enhancement Magnetic Resonance Imaging and the Risk of Stroke in Patients with Atrial Fibrillation","volume":"57","author":"Daccarett","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jjcc.2016.10.014","article-title":"Endothelial\u2013mesenchymal transition in human atrial fibrillation","volume":"69","author":"Kato","year":"2017","journal-title":"J. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"116659","DOI":"10.1016\/j.lfs.2019.116659","article-title":"Reciprocal enhancement of thrombosis by endothelial-to-mesenchymal transition induced by iliac vein compression","volume":"233","author":"Hong","year":"2019","journal-title":"Life Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCEP.113.001322","article-title":"Association of sex hormones, aging, and atrial fibrillation in men: The Framingham Heart Study","volume":"7","author":"Magnani","year":"2014","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.metabol.2014.05.005","article-title":"Testosterone therapy, thrombosis, thrombophilia, cardiovascular events","volume":"63","author":"Glueck","year":"2014","journal-title":"Metabolism"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jacc.2015.06.1313","article-title":"Cardiac Fibrosis in Patients with Atrial Fibrillation: Mechanisms and Clinical Implications","volume":"66","author":"Dzeshka","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.devcel.2006.05.011","article-title":"DeltaEF1 mediates TGF-beta signaling in vascular smooth muscle cell differentiation","volume":"11","author":"Nishimura","year":"2006","journal-title":"Dev. Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/gerona\/glt206","article-title":"Insulin-Like Growth Factor I, Insulin-like Growth factor Binding Protein 3, and Atrial Fibrillation in the Elderly","volume":"69","author":"Duron","year":"2013","journal-title":"J. Gerontol. Ser. A Biol. Sci. Med. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/STROKEAHA.116.016563","article-title":"Serum Insulin-Like Growth Factor 1 and the Risk of Ischemic Stroke: The Framingham Study","volume":"48","author":"Saber","year":"2017","journal-title":"Stroke"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0735-1097(00)00611-2","article-title":"Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation","volume":"35","author":"Goette","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.12659\/MSM.895715","article-title":"Associations of MMP-2, BAX, and Bcl-2 mRNA and Protein Expressions with Development of Atrial Fibrillation","volume":"22","author":"Diao","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gallo, S., Vitacolonna, A., Bonzano, A., Comoglio, P.M., and Crepaldi, T. (2019). ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092164"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijcard.2018.05.068","article-title":"Extracellular signal-regulated kinase (ERK) activation preserves cardiac function in pressure overload induced hypertrophy","volume":"270","author":"Mutlak","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"34882","DOI":"10.1074\/jbc.M404616200","article-title":"Bcl-2 Is a Key Factor for Cardiac Fibroblast Resistance to Programmed Cell Death","volume":"279","author":"Mayorga","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3892\/mmr.2016.5977","article-title":"Expression of Bcl-2 and microRNAs in cardiac tissues of patients with dilated cardiomyopathy","volume":"15","author":"Wang","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1073\/pnas.0710228105","article-title":"Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure","volume":"105","author":"Chen","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","unstructured":"Japanese Circulation Society Joint Working Group (2020, March 12). JCS\/JHRS Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. Available online: http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2018_kurita_nogami.pdf."},{"key":"ref_42","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"ref_43","first-page":"163","article-title":"Low Risk of Major Complications Associated with Pulmonary Vein Antral Isolation for Atrial Fibrillation: Results of 500 Consecutive Ablation Procedures in Patients with Low Prevalence of Structural Heart Disease From a Single Center","volume":"22","author":"Lee","year":"2010","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.hrthm.2011.04.012","article-title":"Long-term single- and multiple-procedure outcome and predictors of success after catheter ablation for persistent atrial fibrillation","volume":"8","author":"Rostock","year":"2011","journal-title":"Heart Rhythm"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e16538","DOI":"10.1097\/MD.0000000000016538","article-title":"Identification of microRNA biomarkers in atrial fibrillation: A protocol for systematic review and bioinformatics analysis","volume":"98","author":"Shen","year":"2019","journal-title":"Medicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/gb-2009-10-6-r64","article-title":"A novel and universal method for microRNA RT-qPCR data normalization","volume":"10","author":"Mestdagh","year":"2009","journal-title":"Genome Biol."},{"key":"ref_47","unstructured":"(2020, March 11). Qiagen, Guidelines for Profiling Biofluid miRNAs. Available online: https:\/\/www.qiagen.com\/us\/-\/media\/project\/qiagen\/qiagen-home\/documents\/content-worlds\/liquid-biopsy\/guidelines-for-profiling-biofluid-mirnas.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1093\/nar\/gkv249","article-title":"Pathway analysis from lists of microRNAs: Common pitfalls and alternative strategy","volume":"43","author":"Godard","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.3390\/ijms11093397","article-title":"Practical Application of Toxicogenomics for Profiling Toxicant-Induced Biological Perturbations","volume":"11","author":"Kiyosawa","year":"2010","journal-title":"Int. J. Mol. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00380-019-01438-6","article-title":"Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: Characteristics of representative reagents in Japan (CVI ARO 7)","volume":"34","author":"Suzuki","year":"2019","journal-title":"Heart Vessels"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00380-019-01501-2","article-title":"Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7)","volume":"35","author":"Suzuki","year":"2020","journal-title":"Heart Vessels"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ymeth.2012.09.015","article-title":"Assessing sample and miRNA profile quality in serum and plasma or other biofluids","volume":"59","author":"Blondal","year":"2013","journal-title":"Methods"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8795","DOI":"10.1038\/s41598-019-45129-8","article-title":"Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses","volume":"9","author":"Madsen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Godard, P., and Page, M. (2016). PCAN: Phenotype consensus analysis to support disease-gene association. BMC Bioinform., 17.","DOI":"10.1186\/s12859-016-1401-2"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wang, Z., Arat, S., Magid-Slav, M., and Brown, J.R. (2018). Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection reveals potential therapeutic targets. BMC Syst. Biol., 12.","DOI":"10.1186\/s12918-017-0524-z"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: A software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/7\/2444\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:14:18Z","timestamp":1760174058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/7\/2444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":56,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["ijms21072444"],"URL":"https:\/\/doi.org\/10.3390\/ijms21072444","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]}}}